Indian-origin researcher develops online tool for the early diagnosis of spinal arthritis

Indian-origin researcher Dr Abhijeet Danve at Yale School of Medicine has developed a simple online screening questionnaire called the A-tool to help detect axial spondyloarthritis (axSpA), a chronic inflammatory condition that causes persistent back pain. Published in Rheumatology Advances in Practice, the pilot study shows that the A-tool can substantially improve the identification of potential cases of axSpA among people with chronic back pain, helping patients reach specialist care earlier when treatment is most effective. The researchers emphasise that the A-tool is a screening aid, not a diagnostic replacement, but it represents a promising step toward reducing years of diagnostic delay.

A quick, patient-facing screen

The A-tool is divided into a three-question prescreen followed by an eight-question screening questionnaire for people with chronic back pain to complete themselves. The questions target key clinical features associated with axSpA such as inflammatory back pain, joint swelling, psoriasis, inflammatory bowel disease and a family history of spondyloarthritis. The screening instrument purposely excludes specialist blood tests and imaging so it can be widely shared through patient portals and social media.

What the pilot study actually found

The pilot was a single-centre study. The investigators enrolled 100 people who responded to the online screener and 86 completed the full clinical evaluation. Of those 86, 29 patients or about 34 percent were clinically diagnosed with axSpA (7 with ankylosing spondylitis and 22 with non-radiographic axSpA). The authors report that, in this recruited population, the A-tool raised the probability of detecting axSpA from roughly 5 percent to about 33 percent, a roughly sixfold increase in case detection in that sample. The paper and the Yale press release note these findings as promising while stressing that further validation is required.

Screening is not diagnosis

A crucial point is that positive screens in the study underwent standard clinical assessment. The diagnostic workup included clinician evaluation and the usual confirmatory tests such as blood markers and imaging when indicated. The A-tool is intended to identify people who should be referred for that diagnostic pathway rather than to replace laboratory or imaging studies.

Strengths and caveats

The A-tool has practical advantages. It is brief, easy to administer online and may empower patients to recognise red flags and seek rheumatology referral sooner. In the pilot the instrument proved feasible to deploy through electronic patient portals and social channels, and it successfully triaged a cohort for specialist assessment.

There are important limitations to bear in mind. This was a single-centre pilot study with modest discriminatory performance. The multivariable model based on the questionnaire responses showed an area under the curve of about 0.66, indicating only moderate ability to distinguish axSpA from other causes of chronic back pain. The agreement between self-reported answers and physician-assessed findings was low to moderate.

The recruited population was self-selected after seeing the online screener, so performance in routine primary care or different health systems may vary. The authors call for larger, multi-centre validation studies before widespread clinical adoption.

Addressing diagnostic delay

Long delays between symptom onset and diagnosis of axSpA are well documented, though estimates vary by study and region. The paper and accompanying commentary note that delays are commonly measured in years and that some studies report average delays that stretch to around a decade. The A-tool is presented as one practical step to shorten those delays by identifying candidates for rheumatology referral earlier.

What this means for patients

If validated more broadly, the A-tool could help reduce unnecessary waiting, speed up referrals to rheumatologists and enable earlier access to effective therapies that prevent progressive spinal damage. For clinicians, it could serve as a low-cost triage aid to highlight patients who need specialist assessment. For now, clinicians and patients should view it as an aid that complements, rather than replaces, clinical judgement and standard diagnostic tests.